Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propofol + midazolam + fentanyl
- Development stage
- Phase 4
- Lead developer
- AkzoNobel
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of three medications used for procedural sedation and analgesia. This regimen combines propofol (a short-acting intravenous anesthetic), midazolam (a benzodiazepine sedative), and fentanyl (an opioid analgesic) to provide effective sedation, amnesia, and pain control during medical procedures. The combination leverages the complementary effects of these medications to achieve desired sedation levels while potentially allowing for lower doses of each individual component.
- Other names
- Propofol, Midazolam, and Fentanyl
02
Targets
GABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on propofol + midazolam + fentanyl.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propofol + midazolam + fentanyl.